PROTOCOL: MRI BRAIN WO-DEMENTIA/ARIA

Dementia, neurodegenerative disorder, memory loss, r/o ARIA

CLINICAL INDICATIONS/

To evaluate for Amyloid-Related Imaging Abnormalities (ARIA) in the setting of dementia medications

HISTORY:

To evaluate for Parkinson's disease and movement disorders

To evaluate for degenerative disease such as progressive supranuclear palsy, multisystem atrophy, corticobasilar degeneration, Creutzfeldt-Jakob, Pick's disease.

POST PROCESSING NOTE: FOR ISJ STUDIES-Please send 3D T1 AND 3D FLAIR to Icometrix for volumetric analysis if requested by ordering provider.

If study being run to evaluate for ARIA in the setting of Lecanemab (Leqembi) then MRI Brain without contrast required prior to 10th, 14th, 28th, and 52nd week after starting intravenous infusions.

TIPS: For Parkinson's disorders, the SWI field of view (see images below) to include substantia nigra in the midbrain. This is the KEY sequence.

SCAN ORDER	PLANE	IMAGE CONTRAST/ WEIGHTING	MODE	PULSE SEQ	COVERAGE		TR RANGE	TE RANGE	ΤI	FLIP ANGLE	THICKNESS/G AP (mm)	FOV (cm)	Max Pixel (mm) Fr x Ph	PHASE AXIS	SEND TO PACS	Max scan time (target)
1	SAG	T2FLAIR	3D	CUBE/ SPACE/ VISTA	COVER ENTIRE HEAD INCLUDING EARS		>5000	~140	VARIES	>130	1-1.2/OVLP	24-25	1.0X1.0	PA	FULL SERIES+ AX/COR 1X1 MPR	6:30
2	AX	SWI / SWAN	3D/2D	GRE/EPI	FORAMEN MAGNUM	VERTEX	VARIES	VARIES/ *40	-	10-15	1-2/OVLP	24	1.0X1.0	RL	FULL SERIES	3:50
3	AX	DWI (b1200)	2D	EPI/ RESOLVE	FORAMEN MAGNUM	VERTEX	>4000	MIN	-	90	5/.5	24	2.5X2.5	АР	FULL SERIES + ADC MAP	3:00
4	SAG	Т1	3D	MPRAGE	COVER ENTIRE H EA	VARIES BY SCANNER				1-1.2/0	24-25	1.0X1.0	PA	FULL SERIES+ AX/COR 1X1 MPR	4:55	
5	AX	Т2	2D	FSE	FORAMEN MAGNUM	VERTEX	4000- 7000	85-125	-	>130	5/.5	24	.75X.75	RL	FULL SERIES	3:00
6	AX	T2FLAIR	2D	FSE	FORAMEN MAGNUM	VERTEX	6000- 15000	140-160	VARIES	>130	5/.5	24	1.0X1.0	АР	FULL SERIES	4:00

